Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model - ScienceDirect
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
Cureus | High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial | Article
Pharmaceutics | Free Full-Text | Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Full article: Tocilizumab (Actemra)
LncRNA MIR31HG is induced by tocilizumab and ameliorates rheumatoid arthritis fibroblast-like synoviocyte-mediated inflammation via miR-214-PTEN-AKT signaling pathway | Aging
Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab - Document - Gale OneFile: Health and Medicine
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study - The Lancet Rheumatology
Comparison of the two tocilizumab strategies used in the economic... | Download Scientific Diagram
761037Orig1s000
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells | PLOS ONE
Tocilizumab reduces deaths in patients hospitalised with COVID-19 — Centre for Tropical Medicine and Global Health
Actemra® 20 mg/mL, concentrate for solution for intravenous (IV) infusion
TropicalMed | Free Full-Text | Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
![The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/10322/1/fig-3-full.png "The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]")
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review [PeerJ]
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial - American Journal of Transplantation
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
Tocilizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Comparison of the two tocilizumab strategies used in the economic model | Download Scientific Diagram
Frontiers | Tocilizumab and COVID-19: Timing of Administration and Efficacy
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine
Health Product InfoWatch: October 2022 - Canada.ca
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
